Johnson & Johnson Aktie News

With the Federal Reserve set to announce its final policy decision of 2025 on Wednesday, investors are rotating into defensive positions. More than the rate-cut possibility (which is around 90% as per recent estimates), the traders are worried about whether the central bank will signal more easing ahead or take a harder stance.

Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.

Investors love S&P 500 dividend stocks, especially those with dependable, high yields, because they provide a substantial passive income stream and offer significant total return potential.

TECVAYLI® and DARZALEX FASPRO® combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up Combination regimen granted Breakthrough Therapy Designation by U.S. FDA ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today annou...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived editi...

Dividend growth investing has always had an appeal to people who are looking to boost their income, find stability in another unstable market, and build long-term wealth.

I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and attractive risk/reward for diversified, income-focused investors. My screen highlights 33 U.S. large caps with ≥25% ROE and ≥2% yield, many trading at compelling valuations.

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second line Data suggest stronger immune fitness in earlier lines may be associated with longer progression free survival ORLANDO, Fla. , Dec. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today updated re...